Merck of Whitehouse Station, New Jersey, has halted development of its lead biogeneric product, MK-2578, a PEGylated erythropoietin-stimulating agent for treating anemia. The decision, announced ...
Merck's CEO Richard Clark has unveiled plans ... The news comes at a time when the Whitehouse Station, New Jersey–based pharma faces dwindling sales of cholesterol-lowering blockbusters Zetia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback